Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005

被引：0
|
作者：
Wisniewski, Mathilde [1 ]
Placide, Pierre-Alain [1 ]
Granier, Sandra [1 ]
Al Shatti, Yacoub [1 ]
Al Qalaf, Shuaib [1 ]
Bouattour, Mohamed [1 ]
Lamuraglia, Michele [1 ]
Hammel, Pascal [1 ]
机构：
[1] Univ Denis Diderot Paris VII, AP HP, Hop Beaujon, Dept Digest & Med Oncol, Clichy, France
来源：
HEPATOBILIARY SURGERY AND NUTRITION | 2018年 / 7卷 / 05期
关键词：
RANDOMIZED CONTROLLED-TRIAL; CANCER; CHEMORADIOTHERAPY; MULTICENTER;
D O I：
10.21037/hbsn.2018.08.03
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：399 / 402
页数：4
相关论文
共 50 条
  • [21] A phase III trial of virulizin plus gemcitabine vs. gemcitabine alone in advanced pancreatic cancer: Results of subgroup analysis.
    Wright, J. A.
    Osterlee, J.
    Fekete, S.
    Lee, Y.
    Young, A. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
  • [22] Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib plus Gemcitabine for Resected Cancer of the Pancreatic Head A Phase II Randomized Clinical Trial
    Abrams, Ross A.
    Winter, Kathryn A.
    Safran, Howard
    Goodman, Karyn A.
    Regine, William F.
    Berger, Adam C.
    Gillin, Michael T.
    Philip, Philip A.
    Lowy, Andrew M.
    Wu, Abraham
    DiPetrillo, Thomas A.
    Corn, Benjamin W.
    Seaward, Samantha A.
    Haddock, Michael G.
    Song, Suisui
    Jiang, Yixing
    Fisher, Barbara J.
    Katz, Alan W.
    Mehta, Sharmila
    Willett, Christopher G.
    Crane, Christopher H.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (03): : 173 - 179
  • [23] ESPAC-4: A Multicenter, International, Randomized Controlled Phase III Trial of Adjuvant Combination Chemotherapy of Gemcitabine (GEM) and Capecitabine (CAP), Versus Monotherapy Gemcitabine in Patients With Resected Pancreatic Ductal Adenocarcinoma
    Neoptolemos, J. P.
    Palmer, D.
    Ghaneh, P.
    Valle, J.
    Cunningham, D.
    Wadsley, J.
    Meyer, T.
    Anthoney, A.
    Glimelius, B.
    Falk, S.
    Lind, P.
    Izbicki, J.
    Middleton, G.
    Ross, P.
    Wasan, H.
    McDonald, A.
    Crosby, T.
    Psarelli, E.
    Hammel, P.
    Buechler, M. W.
    PANCREAS, 2016, 45 (10) : 1529 - 1529
  • [24] Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial
    Tomislav Dragovich
    Mark Huberman
    Daniel D. Von Hoff
    Eric K. Rowinsky
    Paul Nadler
    Debra Wood
    Marta Hamilton
    George Hage
    Julie Wolf
    Amita Patnaik
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 295 - 303
  • [25] Erlotinib plus gemcitabine in patients with unresectable pancreatic carcinoma: Results from a phase IB trial.
    Porterfield, BW
    Dragovich, T
    Patnaik, A
    Rowinsky, E
    Huberman, M
    Clinebell, T
    Hamilton, M
    Zitelli, A
    Nadler, P
    Wood, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 340S - 340S
  • [26] Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial
    Dragovich, Tomislav
    Huberman, Mark
    Von Hov, Daniel D.
    Rowinsky, Eric K.
    Nadler, Paul
    Wood, Debra
    Hamilton, Marta
    Hage, George
    Wolf, Julie
    Patnaik, Amita
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (02) : 295 - 303
  • [27] Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response
    Park, Semi
    Chung, Moon Jae
    Park, Jeong Youp
    Chung, Jae Bock
    Bang, Seungmin
    Park, Seung Woo
    Song, Si Young
    GUT AND LIVER, 2013, 7 (05) : 611 - 615
  • [28] Phase II trial of Erlotinib plus Gemcitabine chemotherapy in Korean patients with advanced pancreatic cancer and prognostic factors of chemotherapeutic response
    Park, Semi
    Bang, Seungmin
    Park, Seung Woo
    Chung, Jae Bock
    Song, Si Young
    CANCER RESEARCH, 2009, 69
  • [29] CONKO-001: FINAL RESULTS OF THE RANDOMIZED, PROSPECTIVE, MULTICENTER PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS OBSERVATION IN PATIENTS WITH RESECTED PANCREATIC CANCER (PC)
    Riess, H.
    Neuhaus, P.
    Post, S.
    Gellert, K.
    Ridwelski, K.
    Schramm, H.
    Zuelke, C.
    Fahlke, J.
    Langrehr, J.
    Oettle, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 45 - 46
  • [30] CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC)
    Neuhaus, P.
    Riess, H.
    Post, S.
    Gellert, K.
    Ridwelski, K.
    Schramm, H.
    Zuelke, C.
    Fahlke, J.
    Langrehr, J.
    Oettle, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345